Is General Motors' (NYSE:GM) self-driving subsidiary worth $43 billion -- already?
That's the eye-popping conclusion that one Wall Street analyst put forth in a note to clients last week. The analyst thinks that GM Cruise, the San Francisco-based GM subsidiary that is gearing up to launch a self-driving taxi business, could become massively profitable over the next decade -- and that makes it worth quite a bit now.
If he's right, and if reports that GM is considering ways to unlock that value are accurate, then it's a powerful addition to the bull case for GM's shares. Let's take a look.
GM Cruise, the automaker's self-driving subsidiary, is developing an electric self-driving taxi based on the Chevrolet Bolt EV. It expects to launch its service at scale in 2019. Image source: General Motors.
$32 billion in revenue in 2030?The analyst in question is Joseph Spak, RBC Capital Markets' auto-industry analyst. In a note to clients last week, he reviewed what we know of GM's plans to begin rolling out a self-driving taxi fleet next year -- and looked at how that fleet could grow over time. His conclusion: GM Cruise could become a very profitable business by 2030.
For now, it appears GM's plans are to run its own transportation network company (TNC). If they can get the technology right and execute on this plan, then when we run this scenario, we see them having a fleet of ~800,000 vehicles by 2030 driving ~58 billion miles that year. At $0.55/mile and 29% EBIT margins, we see ~$17 billion of EBITDA. In our DCF (11x exit multiple) this values Cruise at $43 billion.
If GM is charging $0.55 per mile, and its vehicles drive 58 billion miles in 2030, that works out to $31.9 billion in revenue. Compared to the $145.6 billion in revenue that GM earned in 2017, that sounds more incremental than transformational -- but it's the margin that's the key to his valuation.
Spak's note talks about earnings before interest, taxes, depreciation, and amortization (EBITDA) because that's what one uses in a discounted cash flow analysis (DCF). But just for a moment, to keep it consistent with GM's standard reporting, let's talk about earnings before interest and tax (EBIT) -- or specifically, "EBIT-adjusted" -- GM's term for EBIT minus special items and some other small adjustments.
Spak assumes an EBIT margin of 29% -- far higher than GM's EBIT-adjusted margin of 8.8% in 2017. Applied to the $31.9 billion in revenue that Spak assumes for 2030, we get EBIT of $9.25 billion, which is not far at all from the $12.8 billion in EBIT-adjusted that GM earned last year. (We can ignore the "adjusted" part for now, because we don't have any idea what GM's special items will look like in 2030.)
From there, Spak estimated the EBITDA, used that to run his DCF assuming a multiple of 11 on GM Cruise's 2030 valuation, and came up with a net present value of $43 billion.
Given that GM's total market cap right now is about $55.7 billion, what does that mean for the value of GM's stock?
How much of this is reflected in GM's share price?First, we should note that GM doesn't own 100% of GM Cruise anymore. In May, GM agreed to give SoftBank Group's (NASDAQOTH:SFTBF) Vision Fund a 19.6% stake in Cruise, in exchange for a $2.25 billion investment -- a transaction that valued Cruise at $11.5 billion.
If Spak is right, then SoftBank got a heck of a deal. Of course, so did GM itself, when it bought then-tiny start-up Cruise Automation for $581 million plus employee incentives. GM invested about $600 million in Cruise last year, and it has said that it expects to spend another $1 billion in 2018 as it ramps up toward the commercial launch of its self-driving taxi service next year.
Even at 80.4% of that $11.5 billion (about $9.25 billion), it's clear that GM has already managed a nice return -- on paper, at least. But Spak's valuation is nearly four times the valuation that GM and SoftBank agreed on just two months ago. Is it for real?
The upshot: This is why GM is considering a Cruise spinoffFor now, Spak is hedging his bets quite a bit. His price target for GM's stock is a bullish-but-not-outrageous $53, of which he said the value added by its 80.4% stake in GM Cruise is $7 per share. That values GM's stake in Cruise at about $9.9 billion -- a slight premium over the valuation that GM and SoftBank agreed on in May.
For the moment, that's probably fair. But the evidence is mounting that GM is considering ways to unlock the value of Cruise. (Among other things, Cruise just hired its own heavy-hitter communications director: John Taylor, formerly of SpaceX.) Spak's analysis points up why GM would feel the need to consider such moves. And the possibility adds another reason for investors to think about buying GM's stock now: Any such share issue for Cruise would almost certainly be distributed to existing GM shareholders.
It's hard for growth-minded investors to get too excited about the stock of a century-old automaker (though GM does pay a solid dividend), even if it has a subsidiary that could grow dramatically between now and 2030. But if GM created a way for investors to buy just that growth potential, I suspect it would be quite popular -- and I suspect that Spak's valuation wouldn't be out of line.
Aeon (CURRENCY:AEON) traded 8.8% higher against the US dollar during the 1-day period ending at 18:00 PM E.T. on July 17th. One Aeon coin can currently be purchased for approximately $1.51 or 0.00020733 BTC on major cryptocurrency exchanges including HitBTC, TradeOgre and Bittrex. Aeon has a total market cap of $23.95 million and approximately $24,192.00 worth of Aeon was traded on exchanges in the last 24 hours. In the last week, Aeon has traded up 28.9% against the US dollar. 
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Media stories about Marrone Bio Innovations (NASDAQ:MBII) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Marrone Bio Innovations earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the basic materials company an impact score of 46.1419402737771 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days. 
Equities analysts predict that Tellurian Inc (NASDAQ:TELL) will announce earnings per share of ($0.11) for the current quarter, according to Zacks. Two analysts have issued estimates for Tellurian’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.10). Tellurian reported earnings of ($0.17) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 35.3%. The firm is expected to report its next earnings results on Monday, January 1st.
Equities research analysts forecast that Herc Holdings Inc. (NYSE:HRI) will post $0.08 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Herc’s earnings. Herc posted earnings per share of $0.06 in the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The company is expected to issue its next earnings results on Tuesday, August 14th.
Equities research analysts expect DCT Industrial Trust Inc (NYSE:DCT) to announce earnings of $0.64 per share for the current fiscal quarter, Zacks reports. Five analysts have made estimates for DCT Industrial Trust’s earnings. The lowest EPS estimate is $0.63 and the highest is $0.64. DCT Industrial Trust posted earnings per share of $0.60 in the same quarter last year, which indicates a positive year-over-year growth rate of 6.7%. The business is expected to announce its next quarterly earnings report after the market closes on Thursday, August 2nd.
Verge (CURRENCY:XVG) traded up 1.8% against the US dollar during the 24 hour period ending at 16:00 PM E.T. on July 4th. Verge has a total market cap of $406.02 million and approximately $9.44 million worth of Verge was traded on exchanges in the last 24 hours. One Verge coin can now be bought for about $0.0270 or 0.00000403 BTC on cryptocurrency exchanges including SouthXchange, LiteBit.eu, TradeOgre and Trade Satoshi. During the last week, Verge has traded up 20.8% against the US dollar.